Press releases - Ypsomed

Ypsomed and ten23 health collaborate for the commercialization of the YpsoDose patch injector

16.04.2024 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed enters a partnership with ten23 health, a global Swiss contract development and manufacturing organization. The aim of this collaboration is to advance the commercialization of the YpsoDose wearable injector for the subcutaneous self-injection of large-volume doses. ten23’s drug development, filling and device assembly expertise will significantly contribute to the product offering.

Topics:

Platforms & Operational Excellence

Ypsomed sells its pen needle and BGM business to MTD and invests in the expansion of its Solothurn site

27.03.2024 - 07:00 Ad hoc announcement pursuant to Art. 53 LR

Burgdorf - Ypsomed (SIX: YPSN) and Medical Technology and Devices S.p.A. (MTD) have signed an agreement on the transfer of the pen needle and blood glucose monitoring systems (BGMs) businesses. The transfer to MTD will ensure the long-term supply of a unique pen needle offering. With this step, Ypsomed is focusing its diabetes care business even more strongly on the further development and marketing of the innovative mylife Loop insulin pump solution. As part of its growth strategy, Ypsomed will invest over CHF 100 million over the next four years in the expansion of capacities for autoinjectors at the Solothurn site.

Ypsomed doubles profits and confirms outlook

15.11.2023 - 07:00 Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 15.11.2023, 07:00 a.m. – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 255.4 million in the first six months of the 2023/24 financial year (previous year: CHF 244.2 million).

mylife Loop improves health of pregnant women with type 1 diabetes and their babies

12.10.2023 - 07:00 Press Releases Ypsomed Group

Burgdorf – Pregnant women with type 1 diabetes and their babies benefit from treatment with a hybrid closed loop system based on the CamAPS FX algorithm. This is demonstrated by the AiDAPT clinical study, which clinical outcomes were published in the New England Journal of Medicine and the experience of the pregnant women in Diabetes Technology and Therapeutics, both on 5 October 2023. The algorithm of Ypsomed's mylife Loop, the CamAPS FX app is the only automated insulin delivery (AID) algorithm approved for pregnant women with type 1 diabetes.

Topics:

Innovation & Digital Health

Ypsomed enhances self-injection device platforms with integrated human factors services

05.10.2023 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed announces new Human Factors (HF) services for its pharmaceutical partners to reinforce its position as a leading developer and manufacturer of self-injection solutions. By enhancing its device platform offering with integrated end-to-end HF services, Ypsomed is championing a comprehensive service approach to combination product development that de-risks regulatory approval and expedites time-to-market for its partners. To do so, Ypsomed has entered into a strategic partnership with Interface Analysis Associates LLC (IAA), a leading HF service provider with long-standing expertise in supporting the pharmaceutical industry along the full combination product development journey.

Topics:

Platforms & Operational Excellence